| Theme | Bone tissue regeneration | |
|---|---|---|
| Title | Bone tissue engineering in bone tumor treatment | |
| Publish Date | 2006/10 | |
| Author | Tetsuho Fujimoto | Department of Orthopaedics, Osaka University Graduate School of Medicine |
| Author | Takuji Kizawa | Department of Orthopaedics, Osaka University Graduate School of Medicine |
| Author | Masataka Nishikawa | Department of Orthopaedics, Osaka University Graduate School of Medicine |
| Author | Akira Myoui | Medical Center for Translational Research, Osaka University Hospital |
| Author | Hideki Yoshikawa | Department of Orthopaedics, Osaka University Graduate School of Medicine |
| [ Summary ] | For the treatment of bone defects due to bone tumors, autologous bone grafting has been the commonly accepted treatment. The number of opportunities to use porous bone substitutes, made of calcium phosphate ceramics, has increased. Recently, we developed a porous hydroxyapatite ceramic bone substitute that possesses a fully interconnected porous structure (IP-CHA). Its interconnections allow cell migration and tissue invasion, in vivo, as well as easy introduction of osteoinductive cells or associated factors deep into the pores. In animal experiments, we found IP-CHA an excellent scaffold for bone tissue engineering, in combination with bone marrow derived mesenchymal cells or recombinant human BMP-2. That was because it exhibits osteoconduction, appropriate mechanical strength and a finely interconnected structure, all at the same time. Based on these data, we started a clinical translation research project known as the “Bone Tissue Engineering for Integrating Novel Ceramics Scaffold and Autologous Bone Marrow Derived Mesenchymal Cell”. This was project for the treatment of bone defects in patients with benign bone tumors. However, many issues remain to be solved before applying this technique to the treatment of massive bone voids in patients with malignant bone tumors. | |